Who is sponsoring NCT03335943?

NCT03335943 is sponsored by Chinese Society of Hematology.

What drugs are being tested in NCT03335943?

Interventions in NCT03335943: CDA-2 (Cell Differentiation Agent 2).

What condition does NCT03335943 study?

NCT03335943 studies Myelodysplastic Syndrome (MDS).

Is NCT03335943 still recruiting?

NCT03335943 is currently status unknown. Last updated 8 November 2017.

Last reviewed 2017-11-08 · How we verify

NCT03335943: MD-CHINA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study

Status unknown Phase 4 Last updated 8 November 2017

What this trial tests

Phase 4 trial testing CDA-2 (Cell Differentiation Agent 2) in Myelodysplastic Syndrome (MDS) in 800 participants. Status unknown.

Timeline

1 December 2017

Primary endpoint
1 December 2019

1 December 2020

Quick facts

Lead sponsor	Chinese Society of Hematology
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	800
Start date	1 December 2017
Primary completion	1 December 2019
Estimated completion	1 December 2020

Drugs / interventions tested

CDA-2 (Cell Differentiation Agent 2) — full drug profile →

Conditions studied

Myelodysplastic Syndrome (MDS) — all drugs for Myelodysplastic Syndrome (MDS) →

Sponsor

Chinese Society of Hematology

Who can join

Adults 18 to 85, any sex, with Myelodysplastic Syndrome (MDS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Study aims to evaluate the efficacy and safety of CDA-2 in the treatment of International Prognostic Scoring System (IPSS) Lower/Intermediate-risk myelodysplastic syndrome (MDS) in Chinese patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Myelodysplastic Syndrome (MDS)

Currently open trials in the same condition.

NCT07008820 — Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or · recruiting
NCT03613532 — Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN · Phase 1 · active not recruiting
NCT03173937 — Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilic · Phase 1, PHASE2 · recruiting
NCT02790515 — Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03335943 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese Society of Hematology
Last refreshed: 8 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03335943.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing